Despite the fact that nearly all outcome parameters decreased after 120 min of reperfusion, elevated AF and SV were measured at the 30 min recovery time point in the α-MSH-treated group, relative to control animals. The gene discussed is STAMBP; the disease is atrial fibrillation.